Of all the medical applications of cannabinoids, the use of CBD for treatment-resistant epilepsy has the most robust clinical evidence — including a Phase 3 randomized controlled trial published in the New England Journal of Medicine and an FDA-approved pharmaceutical product. The journey from anecdote to approval is a case study in how rigorous science can validate — and refine — observations that began with patient families.
The story gained widespread attention around 2012–2013, when families of children with Dravet syndrome — a severe, life-threatening epileptic encephalopathy — began reporting dramatic seizure reductions with high-CBD cannabis oil. The scientific community, initially skeptical, responded with urgency: Dravet syndrome carries a roughly 15% mortality rate by age 20, and the existing anticonvulsant drugs frequently fail.
What the Research Shows
The pivotal trial was conducted by Devinsky et al. and published in the New England Journal of Medicine in 2017 [1]. This double-blind, placebo-controlled trial enrolled 120 children and young adults with Dravet syndrome who had failed at least two prior antiseizure medications. Participants received pharmaceutical-grade CBD (Epidiolex) at 20 mg/kg/day or placebo for 14 weeks. The CBD group experienced a median reduction in convulsive seizure frequency of 38.9%, compared to 13.3% in the placebo group — a statistically significant and clinically meaningful difference (p=0.01). Notably, 5% of CBD-treated patients became completely seizure-free, compared to 0% in the placebo group.
A parallel trial by Thiele et al. (2018) in The Lancet examined the sister condition Lennox-Gastaut syndrome (LGS), another catastrophic childhood epilepsy [3]. In a Phase 3 trial of 225 patients, CBD at 20 mg/kg/day reduced drop seizure frequency by 41.9% compared to 17.2% for placebo (p=0.0047). The consistency of findings across two distinct epileptic encephalopathies strengthened confidence in CBD's anticonvulsant mechanism.
The FDA approval of Epidiolex (pharmaceutical-grade CBD) in June 2018 for Dravet syndrome and Lennox-Gastaut syndrome represented the first FDA approval of a cannabis-derived medication in history [2]. This was a landmark regulatory event: it established that cannabinoids could meet the FDA's rigorous standards for pharmaceutical approval, and it provided a clearly defined dosing regimen, pharmacokinetic profile, and safety data from over 500 patients in controlled trials.
CBD's anticonvulsant mechanism appears to involve multiple molecular targets simultaneously, including modulation of sodium channels, enhancement of inhibitory glycine signaling, and indirect effects on the endocannabinoid system. Critically, the anticonvulsant effect of CBD appears independent of CB1 receptor activation — unlike THC — which may explain its favorable tolerability profile in pediatric populations.
Key Findings
Evidence Summary: CBD & Epilepsy
- Devinsky et al. (2017): CBD reduced convulsive seizures by 38.9% vs. 13.3% placebo in Dravet syndrome Phase 3 RCT [1]
- 5% of CBD-treated Dravet patients achieved complete seizure freedom — unprecedented in this population with any drug
- Thiele et al. (2018): CBD reduced drop seizures by 41.9% vs. 17.2% placebo in Lennox-Gastaut syndrome [3]
- FDA approved Epidiolex (pharmaceutical CBD) in June 2018 — first cannabis-derived FDA approval in history [2]
- Epidiolex approval extended to tuberous sclerosis complex in 2020, expanding the evidence base further
- Most common adverse events: somnolence, decreased appetite, diarrhea — generally manageable
- Liver enzyme elevations noted in a subset of patients, particularly those also taking valproate — monitoring required
Expert Perspective
"What we observed in the Dravet trial was remarkable: a reduction in seizure frequency that exceeded what most of these families had seen with any prior medication, in a population where the bar for 'working' is honestly quite low because so many things don't work at all. The FDA approval was the right outcome, and it gives physicians a real tool with real pharmacokinetic data behind it."
— Dr. Orrin Devinsky, Director of the NYU Comprehensive Epilepsy Center and lead author of the 2017 NEJM Dravet trial
What This Means for Patients
The existence of an FDA-approved CBD pharmaceutical (Epidiolex) changes the clinical landscape significantly. For patients with Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex, Epidiolex represents a legitimate, evidence-backed treatment option with defined dosing, drug interaction data, and insurance coverage in most states.
A critical distinction exists between pharmaceutical Epidiolex and commercially available CBD products from dispensaries or supplement retailers. Epidiolex is a pharmaceutical-grade product with documented bioavailability and quality control; over-the-counter CBD oils vary enormously in actual CBD content (studies have found some products contain far less CBD than labeled), lack the clinical trial data, and have unknown interaction profiles.
For epilepsy patients not qualifying for Epidiolex, or in states where access is limited, the research provides biological plausibility for CBD-rich preparations — but families and physicians should exercise caution about product quality and should always coordinate changes with a neurologist, as some anticonvulsant drug interactions require dose adjustments.
Citations
- Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011–2020. doi:10.1056/NEJMoa1611618
- U.S. Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA News Release, June 25, 2018. FDA.gov
- Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4). The Lancet. 2018;391(10125):1085–1096. doi:10.1016/S0140-6736(18)30136-3